Hereditary Angioedema (HAE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Hereditary Angioedema (HAE) Market Outlook

Thelansis’s “Hereditary Angioedema (HAE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hereditary Angioedema treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hereditary Angioedema (HAE) Overview

Hereditary Angioedema (HAE) is a rare genetic disorder marked by the recurrent occurrence of transient subcutaneous and submucosal edemas, leading to swelling and abdominal pain. This condition is characterized by three distinct types, each with its prevalence and clinical manifestations. The hallmark symptoms of HAE include recurrent and unpredictable episodes of swelling in various body parts, such as the face, extremities, genitals, and gastrointestinal tract. Abdominal pain is a common manifestation and can be severe, often leading to unnecessary surgeries due to the misdiagnosis of the acute abdomen. While there is no cure for HAE, effective management strategies aim to control symptoms and reduce the frequency and severity of attacks. Medications such as C1-INH replacement therapy, bradykinin receptor antagonists, and kallikrein inhibitors have shown efficacy in treating and preventing HAE attacks. HAE is estimated to impact approximately 1 in 50,000 individuals, making it a relatively uncommon genetic disease.

• Among the three types of HAE, Type I is the most prevalent, accounting for approximately 85 percent of cases. It is characterized by a deficiency in C1 esterase inhibitor (C1-INH), a crucial protein in regulating inflammation.
• Type II, comprising 15 percent of cases, is also associated with a deficiency in C1-INH but differs in terms of the functionality of the available protein.
• Type III is considered exceptionally rare and is distinguished by normal levels of C1-INH. Unlike Types I and II, the exact genetic cause of Type III HAE is not completely understood. 

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: